order boon continu still earli rais pt
sustain cycl
put mix print top-lin beat ep miss show continu
momentum oncolog order cc cc last rais top line
midpoint order surg driven confluenc factor
earli inning china india us upgrad halcyon see combo
faster convers tariff offset flexibl drive teen ep growth near term
rais pt
global order surg continu strength across key geographi
gross oncolog order reach anoth high actual driven
china apac cc cc last emea cc cc last halcyon
order total momentum across geographi signific
consid key driver region china tata us reimburs yet
formal kick combo healthi demand halycon truebeam
softwar increasingli confid gross order sustain low-
teen
china see inflect point order long-term trend signific
like indic momentum china ahead formal order flow
china licens issu last year time tone bit subdu
rel suggest china licens order flow expect acceler
begin mid-year indic see inflect point time
asid co see china substanti long-term opportun even modest
penetr level would translat doubl us instal base use
asp per system translat capit sale alon time
tata agreement repres signific near- long-term upsid order outlook
earli march co sign agreement tata trust suppli rt system
india next year feedback suggest order flow begin
could includ seri larg purchas agreement progress broadli
india repres opportun similar scale china assum modest penetr
linac per million india popul would translat increment
unit time use asp per system translat
capit sale alon time india
rais pt good place volatil hc tape
goe prior revis gross
oncolog order target goe cc prior cc reflect
higher order flow china class licens award initi contribut
tata agreement india acceler order convers backlog
benefit tariff offset toward back-end year revis pt goe
reflect higher increas confid sustain teen
oncolog order growth next year
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
buy thesi predic gross oncolog order
sustain teen driven china/india uptak us
upgrad maintain lead posit healthi
clip margin upsid halcyon convers
work differenti base sever proprietari survey
w/ us physician kol meet industri wide summit
us-china tariff mitig effort announc
clinic updat softwar flash
low-teen growth global oncolog order support
china demand india uptak us upgrad
value-bas care
reimburs model us
oncolog gm remain stabl rang support
major chang us-china tariff polici
pt reach break-even
larg scale next
pt use blend approach consid pe ebitda
sotp dcf methodolog
mid-teen growth global oncolog order support
china demand india uptak us upgrad
impact transit value-bas care
reimburs model us come
oncolog gm expand support halcyon
us-china tariff polici eas drive ep upsid
pt reach break-even
 next growth ep accret
pt use blend approach consid pe ebitda
sotp dcf methodolog
hsd growth global oncolog order driven slower
china demand india uptak us upgrad
transit value-bas care reimburs model us
oncolog gm declin lower demand price
us-china tariff polici tighten lead
cost ep downsid
pt reach break-even
 next prove growth ep dilut
pt use blend approach consid pe ebitda
sotp dcf methodolog
pleas see import disclosur inform page report
financi summari market data
estim valuat
pleas see import disclosur inform page report
pleas see import disclosur inform page report
